A high surface expression of Epidermal Growth Factor Receptor (EGFR) and low rates of EGFR and k-ras mutations seem to enable the use of cetuximab for anal cancer treatment [20], but only a couple of studies describe a small benefit regarding palliative treatment of anal cancer patients [21,22]. This evidence concerns the gene EGFR and anal carcinoma.